Detection of human and rodent 5-HT$_{3B}$ receptor subunits by anti-peptide polyclonal antibodies

David C Reeves$^{1,2}$ and Sarah CR Lummis$^{*1}$

Address: $^1$Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK and $^2$Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, NY, 10461, USA

Email: David C Reeves - dreeves@aecom.yu.edu; Sarah CR Lummis$^{*}$ - sl120@cam.ac.uk

* Corresponding author

Abstract

Background: The 5-HT$_3$ receptor is a member of a neurotransmitter-gated ion channel family which includes nicotinic acetylcholine, GABA$_A$, and glycine receptors. While antibodies specific for the 5-HT$_{3A}$ receptor subunit are plentiful, and have revealed a wealth of structural and functional information, few antisera exist for the detection of 5-HT$_{3B}$ receptor subunits. Here we describe the generation and characterisation of a rabbit polyclonal antiserum that specifically recognises 5-HT$_{3B}$ receptor subunits.

Results: Immunization of a rabbit with a 20-mer peptide, corresponding to the N-terminus of the human 5-HT$_{3B}$ receptor subunit, generated serum with polyclonal antibodies from which an IgG fraction was purified, yielding pAb77. The antibodies were shown to label 5-HT$_{3B}$ receptor subunits in transfected human embryonic kidney cells and rodent tissues using Western blots. Immunocytochemistry using pAb77 on these cells showed that 5-HT$_{3B}$ receptor subunits do not reach the plasma membrane in the absence of 5-HT$_{3A}$ receptor subunits. Immunohistochemical analysis of rat brain sections showed pAb77 immunoreactivity in distinct populations of cells in the hippocampus.

Conclusion: We have demonstrated that pAb77 antibodies specifically label native and recombinant 5-HT$_{3B}$ receptor subunits with high affinity and specificity. The antibody was shown to be useful for the determination of both receptor trafficking and also mapping 5-HT$_{3B}$ receptor subunit expression in the CNS.

Background

The 5-HT$_3$ receptor is a pentameric neurotransmitter-gated ion channel that acts as a molecular switch at synapses [1]. 5-HT$_3$ receptor antagonists are used clinically for the prevention of emesis, and may be useful in the treatment of irritable bowel syndrome and alcoholism [2]. Interestingly, mice lacking the 5-HT$_{3A}$ receptor subunit were recently shown to possess an anxiolytic phenotype [3], although therapeutic potential in humans appears limited [4]. Five 5-HT$_3$ receptor subunits have been cloned to date [5-7], although only two (5-HT$_{3A}$ and 5-HT$_{3B}$) have been shown to exist in functional receptors. Homomeric 5-HT$_{3A}$ receptors are notable for their sub-pS single channel conductance [8], but co-expression with 5-HT$_{3B}$ receptor subunits increases the conductance to more than 20 pS.
[9]. The pharmacological properties of the heteropentamer are largely unchanged compared with the homopentamer [10,11], although the Ca\textsuperscript{2+} permeability of the heteropentamer may be ablated [12] and recovery from desensitization quickened [13]. Additionally, rodent 5-HT\textsubscript{3A/B} heteromers have reduced sensitivity to picrotoxin [14], and channel gating enhancement by some anaesthetics (especially halothane and chloroform) is markedly attenuated [15]. The stoichiometry of recombinant 5-HT\textsubscript{3A/B} heteromers has recently been determined as BBABA [16] but the stoichiometry of native 5-HT\textsubscript{3} receptors remains to be confirmed.

While expression of 5-HT\textsubscript{3B} receptor subunits has been demonstrated in the peripheral nervous system [17], controversy remains over their presence in the central nervous system (CNS) [18]. In particular, an antiserum previously generated which recognizes 5-HT\textsubscript{3B} receptor subunits (AP86/3, [19]) labelled cells in the rat hippocampus, despite in situ hybridisation and RT-PCR data suggesting absence of the subunit [20,21]. On the other hand, 5-HT\textsubscript{3} receptor expression in the brain is widespread [22] and 5-HT\textsubscript{3B} receptor subunit mRNA has been detected in whole brain lysates [6]. It is possible that the 5-HT\textsubscript{3B} receptor subunit, if expressed in the brain, could be targeted to small, discrete populations of cells. The availability of sensitive and selective antisera could help to clarify these points.

Here we describe the generation, purification and characterisation of polyclonal antibodies (pAb77) to a peptide corresponding to a region of the extracellular domain of the 5-HT\textsubscript{3B} receptor subunit.

Results and discussion

Immunoreactivity of antisera for 5-HT\textsubscript{3B} receptor subunits

Two rabbits (numbered 6376 and 6377) were immunised with coupled peptide every two weeks for a period of approximately two months. Test-bleeds were taken 7–10 days after immunisations. Western blots were used to test each antiserum by probing membranes electroblotted with separated crude lysates of human embryonic kidney (HEK)293 cells stably expressing the human 5-HT\textsubscript{3B} Receptor subunit (not shown). No consistent immunoreactivity was observed for sera from rabbit 6376 or pre-immune serum from either animal. At week 7 and subsequent bleeds, serum from Rabbit 6377 showed a consistent strong immunoreactivity for a 55–60 kDa protein. The predicted molecular weight of human 5-HT\textsubscript{3B} receptor subunits without post-translational modifications is 50.3 kDa. We inferred that this immunoreactivity represented labelling of the 5-HT\textsubscript{3B} receptor subunit.

Serum 6377 was tested at several different dilutions against homogenates of HEK293 cells stably expressing 5-HT\textsubscript{1} receptor subunits. Western blots revealed non-specific labelling of several bands at a dilution of 1:100 of 6377 serum (not shown), but dilutions of 1:2,000 to 1:5,000 labelled a single protein band at 55–60 kDa from lysates of cells expressing either human or mouse 5-HT\textsubscript{3B} receptorsubunits (Figure 1). No labelling was seen with lysates of untransfected cells, with cells expressing 5-HT\textsubscript{3A} receptor subunits, or following pre-incubation of 6377 serum for 15 min with 5 mg/ml of the synthetic peptide (data not shown).

Purified IgG fraction (pAb77) was tested by Western blot for its ability to recognise 5-HT\textsubscript{3B} receptor subunit protein as above. Purified IgG was compared with crude 6377 serum by applying each solution separately as the primary antibody (dilution 1:1000) to nitrocellulose membranes blotted with lysates of HEK293 cells expressing 5-HT\textsubscript{3A} or 5-HT\textsubscript{3B} receptor subunits, untransfected cells, and lysates of N1E-115 cells (Figure 1). In common with the crude serum, pAb77 did not label proteins from untransfected cells or those expressing 5-HT\textsubscript{3A} receptor subunits. pAb77 IgG was shown to retain its capacity to specifically label a 55–60 kDa protein in cells expressing human 5-HT\textsubscript{3B} receptor subunits, with a substantial decrease in non-specific background labelling.

We infer that the pAb77 antibodies are both specific and sensitive for 5-HT\textsubscript{3B} receptor subunits. The previously reported 5-HT\textsubscript{3B} specific antiserum, AP86/3 [19], detected a band of 50–60 kDa at a concentration of 0.14 µg/ml. Our new antiserum appears equally or perhaps more sensitive: We observed labelling at dilutions of 1: 10,000 crude sera (~0.1 µg/ml), with strong bands using 1:5000 pAb77 (~0.2 µg/ml). This latter allowed detection of 5-HT\textsubscript{3B} Receptor subunits in homogenates of N1E-115 cells, which express heteromeric rodent 5-HT\textsubscript{3} receptors [23]. Here pAb77 recognised a 55–60 kDa protein, corresponding to the 5-HT\textsubscript{3B} receptor subunit.

Visualisation of 5-HT\textsubscript{3B} receptor subunits by indirect immunofluorescence

HEK293 cells were transiently transfected with 5-HT\textsubscript{3A} or 5-HT\textsubscript{3B} Receptor subunits alone or in combination, and labelled with either pre-immune serum or final bleed polyclonal serum from rabbit 6377. Typical data is shown in Figure 2. No labelling was observed with pre-immune serum from rabbit 6377 (Fig. 2a). Strong labelling was obtained from permeabilized cells expressing either 5-HT\textsubscript{3B} Receptor subunits alone (Fig. 2b) or in combination with 5-HT\textsubscript{3A} receptor subunits (Fig. 2c). Labelling was also seen around the cell membrane of some non-permeabilised cells transfected with both 5-HT\textsubscript{3A} and 5-HT\textsubscript{3B} receptor subunits (Fig. 2c, right panel). This suggests that at least some 5-HT\textsubscript{3B} Receptor subunits are expressed on the surface in the presence of 5-HT\textsubscript{3A} receptor subunits,
although the majority of the 5-HT\textsubscript{3B} receptor subunits remain intracellular. The presence of 5-HT\textsubscript{3A} receptor subunits on the surface of cells transfected with both 5-HT\textsubscript{3A} and 5-HT\textsubscript{3B} receptor subunits was verified by labelling with pAb120, an antisera selective for 5-HT\textsubscript{3A} receptor subunits [24] (Figure 2d).

The extracellular location of the antisera binding site means that it can be used to probe the location of 5-HT\textsubscript{3B} receptor subunits on the cell membrane. Both 6377 serum and pAb77 IgG were found to produce specific labelling of human 5-HT\textsubscript{3B} receptor subunits expressed in permeabilised HEK293 cells, with low background labelling. Specific labelling of non-permeabilised cells, however, was only seen in the presence of 5-HT\textsubscript{3A} receptor subunits (Fig. 2c), suggesting that these are required for efficient expression of 5-HT\textsubscript{3B} receptor subunits on the surface. Thus our immunofluorescence data concur with previous reports that 5-HT\textsubscript{3B} Receptor subunits remain intracellular unless co-expressed with 5-HT\textsubscript{3A} [29,26].

As the peptide used to generate the polyclonal antibodies corresponds to part of the N-terminal region of the 5-HT\textsubscript{3B} receptor subunit, it corresponds to part of the extracellular domain. Using the recently published structure of the homologous nicotinic acetylcholine receptor [25], we can identify the likely region to which it binds (Fig 3). The peptide used as an immunogen in this study corresponds to the α-helix at the tip of the extracellular domain. This model also reveals why pAb77 may be more sensitive than AP86/3 in non-denaturing immunostaining experiments, as the region against which the latter was raised appears to be partly buried in the folded subunit.

**Immunohistochemical localisation of 5-HT\textsubscript{3B} subunits in rat brain**

The immunogenic peptide from human 5-HT\textsubscript{3B} receptor subunits used in this study is 58% identical to the mouse 5-HT\textsubscript{3B} sequence in that region, and for 89% of the residues the charge and polarity are conserved. The sequences of the cloned 5-HT\textsubscript{3B} receptor subunits from mouse and rat in the region of the peptide used in this study are identical [23]. Western blots of HEK293 cells transfected with mouse 5-HT\textsubscript{3B} receptor subunits or mouse brain (but not liver) homogenates (Figure 1) showed that the polyclonal antibodies specifically labelled a band of approximately 55–60 kDa corresponding to 5-HT\textsubscript{3B} receptor subunits. A further band, of Mr approximately 35 kDa was detected by pAb77 in mouse brain or N1E-115 cell homogenates. An extra 35 kDa band has previously been observed with polyclonal antibodies raised against the 5-HT\textsubscript{3A} receptor subunit, and considered to represent a degradation product [24], although differing glycosylation state or a splice variant are also possibilities.

The antibodies were used in further immunohistochemical experiments to determine the distribution of 5-HT\textsubscript{3B} receptor subunits in rat brain and thereby expand the mapping of 5-HT\textsubscript{3A} receptors previously described [27]. Sections of rat hippocampus were probed with either final bleed serum from rabbit 6377 or pAb77, and the optimal dilution was determined to be 1:1,000–1:5,000. The pattern of labelling was not significantly different between crude 6377 serum and purified pAb77. The data show a general light labelling of neurons plus a stronger staining of certain cells in the pyramidal and molecular layers of the hippocampus (Figure 4).

Similar results were obtained with pAb77 in rat hippocampus as were previously demonstrated for the 5-HT\textsubscript{3A} specific antibody, pAb120, generated in a previous study [24], except that no axonal labelling was seen with pAb77. The lack of axonal labelling by pAb77 could reflect a difference in the sub-cellular distribution of the subunits, although further experiments are required to confirm this. In situ hybridisation using riboprobes has revealed that different cell types in the rat spinal cord can express different combinations of 5-HT\textsubscript{3} receptor subunits. 70% of cells in the rat spinal cord express 5-HT\textsubscript{3A} receptor subunits, but only 50% of those express 5-HT\textsubscript{3B} receptor subunits, while 91% of neurons that express 5-HT\textsubscript{3B} receptor subunits also express 5-HT\textsubscript{3A} [28]. Additionally, it has been shown that differentiation of rat PC-12 cells induced by NGF increases 5-HT\textsubscript{3B} receptor subunit expression [23]. Our data, and that utilizing AP86/3 serum [19], which also produced labelling of rat hippocampal sections, support the presence of 5-HT\textsubscript{3B} Receptor subunits on certain CNS neurons, and suggests that 5-HT\textsubscript{3B} receptor subunits are present at low concentrations and are highly localised in discrete populations. The presence of the 5-HT\textsubscript{3B} Receptor subunit in the CNS may in fact be neuroprotective, as heteropentameric 5-HT\textsubscript{3} receptors have a very low Ca\textsuperscript{2+} permeability relative to homopentameric 5-HT\textsubscript{3A} receptors, which precludes the possibility of Ca\textsuperscript{2+}-induced neurotoxicity in the CNS being due to 5-HT\textsubscript{3A/B} heteropentameric receptors [12].

**Conclusion**

Polyclonal antisera raised against the peptide, \textsuperscript{27}PQDSALYHSKQLLLQKYHK\textsuperscript{46}C, was shown to specifically bind 5-HT\textsubscript{3B} receptor subunits with high affinity, allowing the labelling of human and rodent 5-HT\textsubscript{3B} receptor subunit protein in Western blot, immunocytochemical and immunohistochemical procedures. It was found that the majority of 5-HT\textsubscript{3B} Receptor subunits, when expressed alone, do not reach the cell surface, but that co-expression of 5-HT\textsubscript{3A} with 5-HT\textsubscript{3B} receptor subunits permits expression of 5-HT\textsubscript{3B} Receptor subunits in the plasma membrane, as reported previously [29]. Receptor subunits were observed in rat hippocampal slices, but only in a
small percentage of cells, suggesting they exist in the CNS in low abundance and may be highly localised. This new pAb77 antiserum should help to clarify the location and function of both native and recombinant 5-HT3B receptor subunits.

Methods

Design and synthesis of antigenic peptide

The peptide sequence of the human 5-HT3B receptor subunit was analysed with ANTHEPROT v5.2, [30] and regions of the protein predicted to have a high probability of antigenicity were identified. A second program, ANTI-GENIC, from the EMBOSS molecular biology software suite was used to determine candidate peptides [31]. As very short peptides may decrease antigenicity, candidates of less than thirteen residues were discarded. Peptides with more than fifteen amino acids could increase the chance of antibodies being generated against more than one area of charge density [32] therefore these were also discarded. Candidates not in the predicted N-terminal domain were eliminated to allow extracellular labelling by the antibody. The final choice of the peptide 27PQDSALYHLSKQLLQKYHK46C, was made because it contains a high proportion of charged residues and is in a similar region just C-terminal to the signal peptide to the peptide that was previously used successfully to generate antibodies selective for the 5-HT3A receptor subunit [24]. The final cysteine residue was added to the sequence to allow coupling to the carrier. The peptide sequence was checked by BLAST alignment against the non-redundant sequence database and at lower stringency (E = 100) against all available LGIC subunit sequences [33]. The peptide was found to be unique to 5-HT3B receptor subunit protein. The peptide was synthesised by Research Genetics (Huntsville, AL).

Preparation of antigenic peptide for injection

The immunogenic peptide was coupled to keyhole limpet haemocyanin (KLH) by standard methods [34]. Briefly, 1 ml of a 10 mg/ml solution of KLH in PBS (pH 6.0) was mixed with 1 mg m-maleimidobenzoic acid (MBS) for 30 min. Coupled KLH-MBS was purified using a Sephadex G-25 column equilibrated to pH 7.4. The peptide was reduced with 0.2 M sodium borate for 10 min followed by neutralisation with 1 M HCl. 5 mg of reduced peptide was dissolved in the KLH-MBS solution and stirred for 1 h at room temperature. The coupled peptide was stored at -20°C until required. Two male, New Zealand White, rabbits were injected subcutaneously with 1 mg conjugated peptide, mixed with Freund’s complete adjuvant. At monthly intervals, for three months, rabbits were given booster injections with 1 mg of conjugated peptide mixed
Immunolabelling by pAb77 of 5-HT3A and 5-HT3B receptor subunits expressed in HEK293 cells. Confocal images of HEK293 cells fixed with 4% paraformaldehyde probed with immune sera and visualised by indirect immunofluorescence (FITC). (a) transfection of h5-HT3B probed with pre-immune sera (1:1000); (b) transient transfection of h5-HT3B probed with pAb77 (1:1000); (c) transient transfection of h5-HT3B and m5-HT3A probed with pAb77 (1:1000); (d) permeabilised cells (both panels) transiently transfected with either (left panel) m5-HT3A subunit cDNA, and probed with pAb120 antibody (1:300) or (right panel) m5-HT3A and h5-HT3B cDNA and probed with pAb77. Scale bars represent 10 µM.

Figure 2

Immunolabelling by pAb77 of 5-HT3A and 5-HT3B receptor subunits expressed in HEK293 cells. Confocal images of HEK293 cells fixed with 4% paraformaldehyde probed with immune sera and visualised by indirect immunofluorescence (FITC). (a) transfection of h5-HT3B probed with pre-immune sera (1:1000); (b) transient transfection of h5-HT3B probed with pAb77 (1:1000); (c) transient transfection of h5-HT3B and m5-HT3A probed with pAb77 (1:1000); (d) permeabilised cells (both panels) transiently transfected with either (left panel) m5-HT3A subunit cDNA, and probed with pAb120 antibody (1:300) or (right panel) m5-HT3A and h5-HT3B cDNA and probed with pAb77. Scale bars represent 10 µM.
with Freund’s incomplete adjuvant. A harvest bleed was taken at week 9.

**SDS PAGE and Western blotting**

Lysates of HEK293 cells transiently or stably expressing 5-HT₃ receptor subunits, or N1E-115 cells, were prepared by freezing as previously described [24,35]. For mouse tissues, 200 mg tissue was macerated with a needle in 0.5 ml of extraction buffer containing 200 mM Tris-HCl pH 8.0, 250 mM NaCl, 25 mM EDTA and 0.5% SDS. The solution was incubated at 50 °C for 30 min and centrifuged at 4 °C for 5 min at 14 000 g. Samples of the supernatant were mixed with an equal volume of electrophoresis sample buffer (2% SDS, 100 mM dithiothreitol, 60 mM Tris-HCl pH 6.8, 0.05% bromophenol blue) and heated at 95°C for 5 min. They were then centrifuged at 21 000 g for 5 min and 15 µl loaded per lane on SDS-polyacrylamide gels (10% - 12%) using the Mini-Protean 3 system (Bio-Rad). Semi-dry electrophoretic transfer was used to electroblot the separated proteins onto Hybond-ECL nitrocellulose membranes (Amersham-Pharmacia) at 200 mA for 60–90 min (Biometra, Germany). Membranes were stained using Ponceau S for 5 min to verify complete transfer of proteins from the gel. The membranes were incubated in PBS with 5% dried milk powder (Marvel) for 1 h to block non-specific binding sites and then incubated in primary antibody solution in PBS/milk for 1 h with continuous agitation at room temperature. Membranes were washed four times with PBS and then incubated with secondary antibody (a 1:2000 dilution in PBS/milk of goat anti-rabbit antibody linked with horseradish peroxidase, Sigma, MO). Labelling was visualised using the ECL+ chemiluminescence system (Amersham-Pharmacia). For some blots, Tween 20 was added to the PBS solutions at 0.05% to reduce background labelling. Chemiluminescence was recorded by 10–360 s exposures of Hyperfilm-ECL developed using an automatic film developer (X-Omat; Kodak, US).

**Purification of IgG fraction from immunoreactive serum**

In order to decrease non-specific staining seen with the crude serum from rabbit 6377, an immunoglobulin fraction was affinity purified using a Protein A column. An ImmunoPure Immobilised Protein A column (Pierce, Rockford, IL) was equilibrated with 5 ml Binding Buffer (Pierce). 1 ml of the 6377 final bleed serum was diluted with 1 ml Binding Buffer and added to the column. 10 volumes of Binding Buffer were added to the column and binding was monitored by measuring the absorbance at 280 nm of 1 ml fractions of the flow-through. 5 ml Elution Buffer was added to the column and the eluate containing the IgG was collected. The eluate was concentrated using a Centriprep-10 column (Millipore) following the manufacturer’s instructions to give a final volume of 700 µl (in 1 M Tris-HCl pH 8.0). The purified polyclonal antibody is referred to here as ‘pAb77’.

**Immunocytochemical visualisation of 5-HT₃ receptors**

HEK293 cells were grown on 22 mm glass cover slips and washed three times with Tris-buffered saline (TBS: 0.1 M Tris-HCl pH 7.4, 0.9% NaCl) fixed using 4% paraformaldehyde and then incubated in the appropriate dilution of pAb77 antibody (1:100–1:2000) for 1 h at room temperature. After three further washes with TBS, biotinylated anti-rabbit IgG (Vector, CA) was added at 1:200 in TBS and the cover slips incubated for 1 h at room temperature and washed as before. Fluorescein isothiocyanate avidin D (Vector) was added at a dilution of 1:200 in TBS with

---

**Figure 3**

Model of the 5-HT₃ receptor subunit extracellular domain, based on the structure of the nicotinic acetylcholine receptor, showing the location of peptides corresponding to those used as immunogens for pAb77 (yellow) and AP86/3 (red).
incubation for 1 h at room temperature and washed as above. The cover slips were mounted in Vectashield mounting medium (Vector) and immunofluorescence observed using a Nikon epifluorescence microscope. Photomicrographs were taken using constant exposure times of 50 s on Fuji RealA colour film (ASA 400) using a Nikon camera attached to the microscope. Negatives were printed by AM Photographic (Cambridge, UK) with image brightness equalised to that of the negatives. Confocal images were obtained for some preparations (BioRad-MRC600).

**Immunohistochemical visualisation of 5-HT_{3} receptors**

Immunohistochemistry on tissue sections from rat brain was performed using standard immunofluorescence and immunoperoxidase procedures [27]. All procedures were performed at room temperature unless otherwise stated. Male Wistar rats (200–250 g) were deeply anaesthetized and transcardially perfused with 100 ml 0.9% saline followed by 400 ml 4% paraformaldehyde in 0.1 M phosphate buffer. Brains were removed, postfixed for 2 h and cryoprotected overnight in 15% sucrose in 0.1 M phosphate buffer. Cryostat slide-mounted sections (15 µm), or free floating sections cut on a Vibratome (40 µm), were incubated for 1 h in 10% normal goat serum followed by incubation with either crude 6377 serum (1:500–1:10,000) or purified pAb77 IgG (1:500-1:500) in phosphate buffered saline (PBS) containing 0.2% Triton X-100.

For immunofluorescence, sections were incubated for 48 h in primary antibody then washed in PBS and incubated with tetramethylrhodamine-labelled donkey anti-rabbit IgG (1:200) for 3 h. Sections were washed and mounted in PBS:glycerol (1:3) containing 2.5% 1,4-diazobicyclo (2,2,2)- octane to reduce fading. Sections for the immunoperoxidase procedure were incubated for 48 h in primary antibody and 2 h in biotinylated goat anti-rabbit antiserum (1:400) followed by 2 h in avidin-biotin complex (ABC, Vectastain Kit, Vector Laboratories). Immunoreactivity was detected using the nickel-intensified diaminobenzadine method.

**Abbreviations**

5-HT: 5-hydroxytryptamine; CNS: central nervous system; HEK: human embryonic kidney; KLH: keyhole limpet haemocyanin; MBS: m-maleimidobenzoic acid; TBS: Tris-buffered saline

**Authors' contributions**

DCR carried out all experimental procedures except for certain Western blots and the immunofluorescence experiments, which were performed by SCRL.

**Acknowledgements**

We would like to thank J.V. Priestley and S. Averill, (Queen Mary College, University of London) for help with the rat brain work. We gratefully acknowledge the support of the Wellcome Trust. SCRL is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science. DCR was a Wellcome Trust Prize Student.
References

1. Reeves DC, Lummis SC: The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel. Mol Membr Biol 2002, 19:11-26.

2. Costall S, Naylor RJ: 5-HT3 receptors. Curr Drug Targets Neurol Disord 2004, 3:27-37.

3. Kelley SP, Bratt AM, Hodge CW: Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice. Eur J Pharmacol 2003, 461:19-25.

4. Greenshaw AJ, Overstene PH: The neurotrophin-like effects of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications. Drugs 1997, 53:20-39.

5. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D: Primary structure and functional expression of the 5HT3 receptor, a putative serotonin receptor. Nature 1999, 397:359-363.

6. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF: The 5-HT3B subunit is a major determinant of serotonin receptor function. Nature 1999, 397:359-363.

7. Niesler B, Frank F, Kapeller J, Rappold GA: Cloning, functional mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003, 310:101-111.

8. Brown AM, Hope AG, Lambert JJ, Peters JA: Ion permeation and conduction in a human recombinant 5-HT3B serotonin receptor subunit (h5-HT3A). J Physiol 1998, 507:653-665.

9. Kelley SP, Dunlop JJ, Kirkness EF, Lambert JJ, Peters JA: A cytoplasmic region determines single-channel conductance in 5-HT3 receptors. Nature 2003, 424:321-324.

10. Brady CA, Stanford JM, Ali L, Lin L, Williams JM, Dubin AE, Hope AG, Barnes NM: Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/5B receptors. Neuropharmacology 2001, 41:282-284.

11. Dubin AE, Huvard RD, Andrea MR, Pysit J, Zhu JY, Joy KC, Wilson SJ, Galindo JE, Glass CA, Luo L, Jackson MR, Lovenberg TW, Erlander MG: The pharmacological and functional characteristics of the serotonin 5-HT3A receptor are specifically modified by a 5-HT3B receptor subunit. J Biol Chem 1999, 274:30799-30810.

12. Stewart A, Davies PA, Kirkness EF, Safa P, Hales TG: Introduction of the 5-HT3B subunit alters the functional properties of 5-HT3 receptors native to neuroblastoma cells. Neuropharmacology 2003, 44:214-223.

13. Hapfelmeier G, Tredt C, Hasene der R, Zieglgansberger W, Eisen samer B, Rupprecht R, Rammes G: Antibodies against the extracellular domain of the 5-HT3 receptor label both native and recombinant receptors. Mol Brain Res 1999, 71:221-230.

14. Das P, Dillon GH: The 5-HT3B subunit confers reduced sensitivity to picrotoxin when co-expressed with the 5-HT3A receptor subunit. J Physiol 1984, 344:1720-1733.

15. Das P, Dillon GH: The 5-HT3B subunit confers reduced sensitivity to picrotoxin when co-expressed with the 5-HT3A receptor subunit. J Physiol 1984, 344:1720-1733.

16. Solt K, Stevens RJ, Davies PA, Raines DE: General Anesthetic-induced Channel Gating Enhancement of 5-HT3 Receptors is Dependent on Receptor Subunit Composition. J Pharmacol Exp Ther 2005, 315:771-776.

17. Barrera NP, Herbert P, Henderson RM, Martin IL, Edson JM: Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. Proc Natl Acad Sci USA 2005, 102:12595-12600.

18. Michel K, Zeller F, Langer R, Nekarda H, Kruger D, Dover TJ, Brady CA, Barnes NM, Schernmann M: Serotonin excites neurons in the human submucous plexus via 5-HT3 receptors. Gastroenterology 2005, 128:1317-1326.

19. van Hoof JA, Yakel JL: 5-HT3 receptors in the CNS: 3B or not 3B? Trends Pharmacol Sci 2003, 24:157-160.

20. van Hoof JA, Dessi K, Brady CA, Williams JM, Lin L, Princivalle A, Hope AG, Barnes NM: Generation of a selective 5-HT3B subunit-recognising polyclonal antibody; identification of immunoreactive cells in rat hippocampus. Neuropharmacology 2001, 41:1013-1016.

21. Morales M, Wang SD: Differential composition of 5-hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral nervous system. J Neurosci 2002, 22:6732-6741.

22. Sudweeks SN, Hooft JJA, Yakel JL: Serotonin 5-HT3 receptors in rat CA1 hippocampal interneurons: functional and molecular characterization. J Physiol 2002, 544:715-726.

23. Hansma MC, Davies PA, Hales TG, Kirkness EF: Evidence for expression of heteromeric serotonin 5-HT3 receptors in rodents. J Neurochem 2000, 75:240-247.

24. Spier AD, Wooterspoon G, Yasak SV, Nichols RA, Priestley JV, Lummis SCR: Antibodies against the extracellular domain of the 5-HT3 receptor label both native and recombinant receptors. Mol Brain Res 1999, 71:221-230.

25. Unwin N: Defined Structure of the Nicotinic Acetylcholine Receptor at 4 A Resolution. J Mol Biol 2005, 346:967-989.

26. Boyd GW, Doward A, Kirkness EF, Millar NS, Connolly CN: Cell surface expression of 5-hydroxytryptamine type 3 receptors is controlled by an endoplasmic reticulum retention signal. J Biol Chem 2003, 278:27681-27687.

27. Priestley JV, Wooterspoon G, Lummis SCR, McMahon HT, Spier AD: Immunocytochemical analysis of 5-HT3 receptor distribution in the rat CNS. Soc Neurosci Abs 1997, 23:482.10.

28. Morales M, McCollum N, Kirkness EF: 5-HT3-receptor subunits A and B are co-expressed in neurons of the dorsal root ganglion. J Comp Neurol 2001, 438:163-172.

29. Boyd GW, Low P, Dunlop JJ, Robertson LA, Vardy A, Lambert JJ, Peters JA, Connolly CN: Assembly and cell surface expression of homomeric and heteromeric 5-HT3 receptors: the role of oligomerization and chaperone proteins. Mol Cell Neurosci 2002, 21:38-50.

30. Delage G, Clerc FF, Roux B, Gautheron DC: ANTHEIPT: A package of protein sequence analysis using a microcomputer. Comput Appl Biotechnol 1988, 4:351-356.

31. Rice P, Longden I, Bleasby A: EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 2000, 16:276-277.

32. Maelicke A, Plumer-Wilk R, Fels G, Engelhard M, Veltel D: Epitope mapping employing antibodies raised against short synthetic peptides: a study of the nicotinic acetylcholine receptor. Biochemistry 1989, 28:1396-1405.

33. Le Novère N, Changeux J-P: LGICdb: the ligand-gated ion channel database. Nucleic Acids Res 2001, 29:294.

34. Sambrook J, Fritsch ET, Maniatis T: Molecular cloning – a laboratory manual New York: Cold Spring Harbor Laboratory Press; 1989.

35. Hargreaves AC, Taylor CW, Lummis SCR: Ca2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors. Mol Pharmacol 1994, 46:1120-1128.

Publish with BioMed Central and every scientist can read your work free of charge

“BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime.”
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- available free of charge to the entire biomedical community

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp